Study of The role of disease modifying therapies in rate and severity of COVID-19 infection in a cohort of multiple-sclerosis and neuromyelitis optica spectrum disorder
Latest Information Update: 19 Dec 2021
At a glance
- Drugs Azathioprine (Primary) ; Dimethyl fumarate (Primary) ; Fingolimod (Primary) ; Interferon beta modulators (Primary) ; Natalizumab (Primary) ; Rituximab (Primary) ; Teriflunomide (Primary)
- Indications Multiple sclerosis; Neuromyelitis optica
- Focus Adverse reactions
- 19 Dec 2021 New trial record